| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00004872-200306000-00012 |
| P698 | PubMed publication ID | 12777949 |
| P2093 | author name string | Ming Yu | |
| Carol Moreno | |||
| Richard J Roman | |||
| Kimberly M Hoagland | |||
| Mahesh Mistry | |||
| Annette Dahly | |||
| Katie Ditter | |||
| P433 | issue | 6 | |
| P304 | page(s) | 1125-1135 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Journal of Hypertension | Q6295318 |
| P1476 | title | Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats | |
| P478 | volume | 21 |
| Q39544576 | A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. |
| Q41070874 | A Novel GLP1 Receptor Interacting Protein ATP6ap2 Regulates Insulin Secretion in Pancreatic Beta Cells |
| Q36570453 | A custom rat and baboon hypertension gene array to compare experimental models. |
| Q58447525 | Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow |
| Q41811427 | Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats |
| Q37382874 | Alleviation of hyperglycemia induced vascular endothelial injury by exenatide might be related to the reduction of nitrooxidative stress |
| Q49027654 | Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. |
| Q26749495 | Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists |
| Q26752255 | Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? |
| Q33993725 | Cardiovascular and hemodynamic effects of glucagon-like peptide-1. |
| Q97884553 | Cardiovascular effects of antiobesity drugs: are the new medicines all the same? |
| Q37977336 | Cardiovascular effects of incretin-based therapies |
| Q36302662 | Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes |
| Q90183205 | Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats |
| Q39255963 | Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor |
| Q36073461 | Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists |
| Q43054868 | DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure |
| Q33949425 | Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies |
| Q39103371 | Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. |
| Q61798288 | Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension |
| Q36946065 | Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats |
| Q38132470 | Direct cardiovascular effects of glucagon like peptide-1. |
| Q44896182 | Early improvement in albuminuria in non-diabetic patients after Roux-en-Y bariatric surgery |
| Q39413684 | Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats |
| Q39905736 | Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study |
| Q60918453 | Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials |
| Q41873186 | Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats |
| Q38208950 | Effects of GLP-1 in the kidney |
| Q44620317 | Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes |
| Q53886146 | Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. |
| Q37951097 | Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension |
| Q37501142 | Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. |
| Q37395298 | Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? |
| Q35182125 | Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner |
| Q34784085 | Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy |
| Q35769564 | Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans |
| Q36454284 | Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure |
| Q35778740 | Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways |
| Q38065321 | Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes |
| Q38709406 | GLP-1 Agonists and Blood Pressure: A Review of the Evidence. |
| Q27024984 | GLP-1 and cardioprotection: from bench to bedside |
| Q30407530 | GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans |
| Q34336097 | GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure |
| Q36406821 | GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. |
| Q38122396 | GLP-1 receptor agonists: effects on cardiovascular risk reduction |
| Q38238288 | GLP-1: benefits beyond pancreas. |
| Q39204264 | Gastrointestinal Tract: a Promising Target for the Management of Hypertension |
| Q39164330 | Gastrointestinal-Renal Axis: Role in the Regulation of Blood Pressure |
| Q30277035 | Gastrorenal Axis |
| Q30421544 | Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism |
| Q30371576 | Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistance |
| Q36980756 | Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection |
| Q39234083 | Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells |
| Q48131140 | Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors |
| Q38033468 | Glucagon-like peptide-1 and its cardiovascular effects |
| Q41267217 | Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure |
| Q42415270 | Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. |
| Q34196210 | Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation |
| Q36527908 | Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. |
| Q36976775 | Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study |
| Q84286238 | Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes |
| Q37825946 | Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. |
| Q90632374 | Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease |
| Q33603384 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas |
| Q37762321 | Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. |
| Q63353229 | Hypertension |
| Q93005740 | Hypertension as a Metabolic Disorder and the Novel Role of the Gut |
| Q33804594 | Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes |
| Q92619440 | Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases |
| Q45355551 | Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressin |
| Q37760515 | Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects |
| Q26784211 | Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease |
| Q37082698 | Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering |
| Q42627337 | Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure |
| Q51395159 | Insulin resistance in young, lean male subjects with essential hypertension. |
| Q38182499 | Is there a role for the incretin system in blood pressure regulation? |
| Q38511039 | Lipid effects and cardiovascular disease risk associated with glucose-lowering medications. |
| Q54588963 | Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. |
| Q37828337 | Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies |
| Q36312680 | Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice |
| Q26777994 | Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? |
| Q26749189 | Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist |
| Q37260330 | Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. |
| Q35968092 | Pleiotropic effects of incretins |
| Q28076059 | Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association |
| Q35249760 | Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins |
| Q42970295 | Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHR. |
| Q37990619 | Potential cardiovascular effects of incretin-based therapies |
| Q38219481 | Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus |
| Q34410188 | Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity |
| Q33521451 | Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists |
| Q43272349 | Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q38042110 | Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease |
| Q56771767 | Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy |
| Q37197094 | Role of postprandial hyperglycemia in cardiovascular disease |
| Q34994502 | Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes |
| Q33608090 | Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus |
| Q37270524 | Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors |
| Q50994560 | The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. |
| Q36265221 | The GLP-1 system as a therapeutic target |
| Q36368998 | The cardiovascular effects of GLP-1 receptor agonists |
| Q37980019 | The effect of glucagon-like peptide 1 on cardiovascular risk |
| Q42533774 | The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats |
| Q38174491 | The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? |
| Q38227648 | The potential for renoprotection with incretin-based drugs |
| Q46161355 | The role of incretins in cardiovascular control |
| Q36783865 | Therapy in the early stage: incretins |
| Q40036848 | Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists? |
| Q35997260 | Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension |
| Q39260864 | Understanding the cardiovascular effects of incretin. |
| Q38006504 | Update on incretin hormones |
| Q28073342 | Update on the treatment of type 2 diabetes mellitus |
| Q35179865 | Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes |
| Q54522495 | [Cardiovascular effects of incretin-based therapies]. |
Search more.